18
Participants
Start Date
November 8, 2018
Primary Completion Date
June 14, 2019
Study Completion Date
December 16, 2019
ASTX727 + Day 2 Food
ASTX727 is an oral drug product composed of a fixed-dose combination of cedazuridine (E7727), a CDA inhibitor, and decitabine. Food is a high-calorie, high-fat breakfast meal of 800-1000 calories given on Day 2.
ASTX727 + Day 4 Food
ASTX727 is an oral drug product composed of a fixed-dose combination of cedazuridine (E7727), a CDA inhibitor, and decitabine. Food is a high-calorie, high-fat breakfast meal of 800-1000 calories given on Day 4.
Roswell Park, Buffalo
Vanderbilt, Nashville
Gabrail Cancer Center, Canton
Mays Cancer Center UT Health San Antonio MD Anderson Cancer Center, San Antonio
Lead Sponsor
Astex Pharmaceuticals, Inc.
INDUSTRY